New hope for Hard-to-Treat depression in seniors: esketamine spray vs aripiprazole
NCT ID NCT07153406
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two add-on treatments—esketamine nasal spray and aripiprazole pills—for older adults (60-74) whose depression hasn't improved with standard antidepressants. Around 220 participants will receive either esketamine once or twice weekly or daily aripiprazole, alongside their current medication. The goal is to see which approach better reduces depressive symptoms and is safer over 32 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Esketamine nasal spray (flexible doses 28-84 mg) and oral aripiprazole (5-30 mg daily)
What this could lead to
If esketamine works better than aripiprazole, it could offer a new, fast-acting option for older adults with hard-to-treat depression.
What could go wrong
This is an early-phase 3 trial with no results yet. Esketamine may cause side effects like dizziness or dissociation, and the benefit over existing treatments is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro Sociosanitario Hermanas Hospitalarias de Palencia
Palencia, 34004, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clínica Psiquiátrica Padre Menni
Pamplona, Navarre, 31014, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Corporacion Sanitaria Parc Tauli
Sabadell, 08208, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Benito Menni y Fidmag Hermanas Hospitalarias
Barcelona, 08830, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital De La Santa Creu i Sant Pau
Barcelona, 08041, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Mare de Déu de La Mercè
Barcelona, 08042, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Sagrat Cor. Martorell
Barcelona, 08760, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Vall d'Hebron
Barcelona, 08014, Spain